Deerfield Management Company, L.P. (Series C) Nuvalent, Inc. Transaction History
Deerfield Management Company, L.P. (Series C)
- $3.95 Billion
- Q1 2025
A detailed history of Deerfield Management Company, L.P. (Series C) transactions in Nuvalent, Inc. stock. As of the latest transaction made, Deerfield Management Company, L.P. (Series C) holds 17,991,024 shares of NUVL stock, worth $1.39 Billion. This represents 32.3% of its overall portfolio holdings.
Number of Shares
17,991,024
Previous 17,991,024
-0.0%
Holding current value
$1.39 Billion
Previous $1.41 Billion
9.4%
% of portfolio
32.3%
Previous 34.87%
Shares
3 transactions
Others Institutions Holding NUVL
# of Institutions
217Shares Held
60.9MCall Options Held
311KPut Options Held
175K-
Paradigm Biocapital Advisors LP New York, NY5.27MShares$407 Million19.15% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.44MShares$343 Million0.01% of portfolio
-
Black Rock Inc. New York, NY3.02MShares$234 Million0.01% of portfolio
-
Commodore Capital LP New York, NY1.86MShares$143 Million12.88% of portfolio
-
Perceptive Advisors LLC New York, NY1.63MShares$126 Million4.85% of portfolio
About Nuvalent, Inc.
- Ticker NUVL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 42,977,800
- Market Cap $3.32B
- Description
- Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...